Development & Aid, Headlines, Health, North America

HEALTH-U.S.: Problems Plague Anthrax Drug Stocks

Katherine Stapp

NEW YORK, Oct 20 2001 (IPS) - As anonymous letters containing powdered anthrax spores sow fear in the United States and abroad, authorities here are scrambling to make treatments and a vaccine for the deadly bacterium more widely available.

It is not known who sent the letters. More than three dozen people in the states of Florida and New York and in Washington DC, including postal employees who handled the contaminated mail, have been exposed so far. Five people have been infected and one has died.

None of the targets – including television news personalities, Senate Majority Leader Tom Daschle, and New York Governor George Pataki – have been infected.

Anthrax can be transmitted by skin contact, by inhaling spores, or by eating meat from infected livestock. It is most virulent when inhaled. It causes blistery lesions and flu-like symptoms and, if left untreated, kills about one-fifth of those infected. However, antibiotics have proven effective if taken shortly after infection.

The antibiotics can be bought in most pharmacies without a prescription, although stocks are generally considered insufficient to treat a major outbreak. A vaccine also is available but the entire U.S. stockpile is owned by the Department of Defence and is not available to civilians.

The German company Bayer A.G. currently holds a patent on the anthrax antibiotic ciprofloxacin, known by the brand name Cipro. Under mounting pressure to permit generic production of the drug, Bayer says it can handle demand and plans to triple production of Cipro in the United States to more than 200 million tablets.

But on Thursday, citing “extraordinary” circumstances, Canada announced it planned to manufacture a generic version of Cipro. India also has said it is ready to produce and ship ciprofloxacin abroad at an “attractive price.”

A Bayer spokesperson responded that the company “take(s) patent infringement very seriously, and we are prepared to consider all options in order to defend our patents” – leaving open the possibility of a lawsuit.

Although the United States so far has rejected overturning Bayer’s patent on Cipro, which expires at the end of 2003, a bill is currently moving through Congress that would require drug companies to disclose patent settlement deals – agreements whereby they essentially pay off competitors not to market generic versions of brand-name drugs.

Such deals could violate U.S. anti-monopoly laws, in addition to costing consumers hundreds of millions of dollars, according to the U.S. Federal Trade Commission.

The U.S. government introduced in 1998 a mandatory anthrax vaccination programme for all U.S. troops as part of a multi- billion-dollar bio-warfare defence plan. But the shots – six initially, followed by annual boosters – became highly unpopular when about three percent of those inoculated experienced vertigo, joint pain, headaches and other, more severe side effects like lupus and gastrointestinal paralysis.

More than 400 members of the armed forces have refused the vaccine, leading to prosecution in military court and early discharge from service. A survey by the General Accounting Office of the U.S. Congress found that one-fourth of personnel who left the Air National Guard and Air Force Reserve cited apprehension about the anthrax programme as the biggest factor in their decision.

Critics also have alleged a link between the vaccine and Gulf War Syndrome.

Last year, a Congressional panel recommended that the anthrax vaccinations be suspended until proven safe. The Pentagon rejected this advice but was forced to halt the programme in July due to dwindling supplies.

The only U.S. anthrax vaccine maker is BioPort Corp., which this week applied to the U.S. Food and Drug Administration (FDA) for approval to distribute the vaccine after a three-year hiatus due to quality control problems at its manufacturing plant. The average FDA response time is four months but this could be stepped up due to the urgency of the situation.

Critics of the BioPort vaccine, including former and current military personnel, promptly filed their own petition with the FDA this week asking the agency to classify it as Category II – unsafe, ineffective, or misbranded – and to declare the current stocks adulterated.

Kathryn Hubbell, president of the Anthrax Vaccine Network, a support group for members of the military, calls the BioPort vaccine “illegal” and “nothing less than medical experimentation upon the troops.”

The company says renovations at its plant have solved the problems and Defence Secretary Donald Rumsfeld has said that although “things have not been going swimmingly” for BioPort, it would get “one more crack at getting the job done.”

Meanwhile, other companies are cashing in on public concerns about bio-terrorism.

Two U.S. companies that are working on anthrax vaccines, Avant Immunotherapeutics, Inc., and Corixa Corp., have seen their stock prices soar up to 50 percent since the start of the month.

Rubber glove companies in Asia also have been given a boost since the terrorist attacks on New York and the Pentagon heightened fears of bio-warfare.

The U.S. military and the National Institutes of Health are developing their own anthrax vaccines, which they say will be ready for clinical trials in the next few months.

It is still uncertain who is behind the anthrax scare, or even that all the letters originated with the same group or individual.

There are dozens of labs around the United States – no one knows exactly how many – that have anthrax stores for research, mostly veterinary. At least 24 countries around the world have stockpiles of anthrax, and many others hold it surreptitiously.

Although some of the letters reportedly contained references to Allah, the Federal Bureau of Investigation says it is not convinced that they are connected to the Sep. 11 terrorist attacks and is still “looking strongly” at the possibility that domestic right-wing extremists are involved.

Vincent Cannistraro, a former counter-terrorism expert with the Central Intelligence Agency, told the Washington Post that “it just doesn’t have the fingerprints of a (suspected terrorist Osama) bin Laden operation.”

Bin Laden’s network “al-Qaeda wants to inflict mass casualties and kill as many people as they can. Sending individual, targeted mailings is not going to accomplish that,” he said. “This might turn out to be someone else trying to fly in under the radar.”

 
Republish | | Print |

Related Tags